Zefeng Lai | Drug Delivery Systems | Excellence in Pharmaceutical Innovation Award

Prof. Dr. Zefeng Lai | Drug Delivery Systems | Excellence in Pharmaceutical Innovation Award

Guangxi Medical University | China

Prof. Dr. Zefeng Lai is a leading figure in the field of pharmaceutical science, recognized for his pioneering work in nanomedicine, drug delivery, and nanotoxicology. He serves as a Professor of Pharmaceutical Science at the School of Pharmacy, Guangxi Medical University, Nanning, China, where he has made outstanding contributions to biomedical research and academic development. Having earned his BSc and PhD from the State Key Laboratory of Crystal Materials, Shandong University, and completed postdoctoral research in Drug Delivery and Biomedical Effects of Nanomaterials, Dr. Lai’s expertise integrates material chemistry with pharmacological innovation to enhance therapeutic outcomes.His research explores the mechanisms and biomedical applications of carbon-based nanodrug carriers, focusing on their transcytosis, biodistribution, and immunological effects. He has led multiple high-impact national and provincial projects, including investigations into mesona chinensis polysaccharides, fibrinolytic enzymes from marine sources, and liver-targeted nanocarriers. His work on the biotoxicity of carboxylated single-walled carbon nanotubes using zebrafish and mammalian models has been particularly influential, advancing the global understanding of nanomaterial safety in pharmaceutical formulations.Prof. Lai’s scholarly influence is reflected in his strong research metrics, with 293 citations across 279 documents, based on 19 published papers, and an impressive h-index of 10, demonstrating his consistent impact and the recognition of his contributions by the global scientific community.His groundbreaking publications demonstrate his multidisciplinary research vision. His paper Photothermal Therapeutic Gold Nanoparticles Loaded with PD-L1 siRNA Enhanced Killing of NSCLC Cells by Immune Cells presents a novel nanoplatform integrating photothermal therapy and immunomodulation for non-small cell lung cancer treatment. His work Immunogenic Nano-Phthalocyanine Enables Oxygen-Economic Photodynamic Therapy for Hepatocellular Carcinoma introduces a new generation of oxygen-efficient nanotherapeutics for liver cancer. Other notable studies include Effect of Carboxylated Single-Walled Carbon Nanotubes on the Development and Morphology of Zebrafish Embryos, High Throughput CircRNA Sequencing Analysis Reveals Novel Insights into the Mechanism of Nitidine Chloride against Hepatocellular Carcinoma, and Toxic Effect of Long-Term Intravenous Injection of Carboxylated Single-Walled Carbon Nanotubes on Kidney in Rats. His research on Nitidine Chloride Induced Colorectal Cancer HT29 Cells Apoptosis Through the Cytochrome c-Mediated Mitochondrial Pathways and Long-Term Intravenous Administration of Carboxylated Single-Walled Carbon Nanotubes Induces Persistent Accumulation in the Lungs and Pulmonary Fibrosis via the NF-ΞΊB Pathway underscores his deep engagement with molecular pharmacology and nanotoxicology.

Profile: Scopus

Featured Publications

Lai, Z., Liu, Y., He, L., Wang, X., Zhang, H., & Zhao, J. (2023). Immunogenic nano-phthalocyanine enables oxygen-economic photodynamic therapy for hepatocellular carcinoma. Biomaterials, 295, 121992.

Yilong Wang | Drug Delivery Systems | Best Researcher Award

Yilong Wang | Drug Delivery Systems | Best Researcher Award

Prof Yilong Wang, Beijing Tiantan Hospital, Capital Medical University, China

Dr. Yilong Wang, Executive Vice President of Beijing Tiantan Hospital, Capital Medical University, is a distinguished neurologist and scientist. With an MD and PhD in Neurology, he has pioneered research in stroke and rare neurological disorders. Author of 301 impactful journal articles and holder of 12 patents, his innovative work spans drug delivery systems and precision medicine. Honored with the 2023 Paul Dudley White International Award, he has also authored several clinical neurology manuals. His cutting-edge contributions, including transcranial drug delivery devices, underscore his commitment to advancing global healthcare. πŸŒπŸ“š

Publication Profile

google scholar

Academic and Professional Background

Professor Yilong Wang πŸŽ“, an accomplished neurologist, earned his MBBS and MSc from North China University of Science and Technology, followed by an MD and PhD in Neurology from Capital Medical University. He completed postdoctoral training at the University of San Francisco πŸŒ‰. Currently serving as Executive Vice President and Chief Scientist at Beijing Tiantan Hospital πŸ₯, Prof. Wang has led groundbreaking research in stroke and rare neurological diseases 🧠. Over the past five years, he has published 72 high-impact papers πŸ“„, holds 12 patents, and made significant strides in precision medicine and drug delivery systems πŸ’Š, earning prestigious accolades like the 2023 Paul Dudley White International Award πŸ†.

Editorial Appointments

Β Professor Yilong Wang πŸ§‘β€βš•οΈ holds prominent editorial roles, serving as the Assistant Editor-in-Chief of Stroke & Vascular Neurology πŸ“š, Deputy Editor-in-Chief of the Chinese Journal of Cerebrovascular Diseases 🧠, and as an editorial board member of the Chinese Journal of Stroke ✍️. His collaborative efforts extend to leading institutions, including the Frontier Medical Interdisciplinary and Translational Center at the National Center for Neurological Disorders 🌐 and the Beijing Brain Science and Brain-Inspired Research Center 🧬. These partnerships underscore his commitment to advancing neurological research and fostering innovation in cerebrovascular and brain science πŸ₯.

Professional Memberships

Professor Yilong Wang πŸ§‘β€βš•οΈ plays key leadership roles in various prestigious organizations. He serves as Vice Chairman of the Expert Committee for the National Health Commission’s Million Disability Reduction Project 🌟, demonstrating his dedication to public health. Prof. Wang is also the Deputy Leader of the Youth Group of the 8th Committee of the Neurology Branch of the Chinese Medical Association 🧠. Additionally, he is the Executive Vice Chairman of the Youth Working Committee of the Chinese Stroke Association πŸ’Ό and Vice Chairman of the Cerebral Small Vessel Disease Branch of the Chinese Stroke Association 🩺, driving innovation in neurological care.

Areas of Research

Professor Yilong Wang πŸ§‘β€βš•οΈ specializes in clinical and translational research on cerebrovascular diseases and rare neurological disorders 🧠, with a focus on interdisciplinary medical-engineering innovations βš™οΈ. His research includes precision medicine for ischemic stroke 🩺, developing technologies for accurate diagnosis and treatment. He pioneers innovative drug delivery systems πŸ’Š, utilizing skull bone marrow-dura-lymphatic pathways to bypass the blood-brain barrier for safe intracranial drug delivery. Prof. Wang also investigates the pathogenesis, diagnostics, and interventions for cerebral small vessel disease and rare neurological disorders 🌐. Additionally, he advances intelligent skull flaps, smart drug delivery systems, and brain-computer interfaces πŸ€–.

Contributions

Professor Yilong Wang πŸ§‘β€βš•οΈ, a renowned neurologist at Beijing Tiantan Hospital πŸ₯, has revolutionized stroke and rare neurological disease research 🧠. Over the past five years, he has published 72 high-impact papers in top journals like NEJM, JAMA, and BMJ πŸ“„ and holds 12 patents, with 2 successfully translated into clinical applications 🌟. His innovations include extending the time window for dual antiplatelet therapy, developing drugs for microcirculation disorders, and pioneering skull-based drug delivery systems to bypass the blood-brain barrier πŸ’Š. Recipient of the 2023 Paul Dudley White International Award πŸ†, Prof. Wang has advanced precision medicine and rare disease research, improving global patient care 🌍.

Research Focus

Professor Yilong Wang is a distinguished researcher focusing on neurology, particularly stroke epidemiology, prevention, and management, and the application of artificial intelligence (AI) in healthcare. His work spans from analyzing stroke prevalence in China to exploring treatment strategies, including antiplatelet therapies and real-world applications of AI in medical practice. With a robust emphasis on stroke prevention, outcomes, and treatment innovation, his contributions bridge advanced research and clinical practice. Wang’s research also addresses the broader implications of healthcare technologies, underscoring their transformative potential. πŸ§ πŸ’ŠπŸ“Š

Publication Top Notes

Artificial intelligence in healthcare: past, present and future

Prevalence, incidence, and mortality of stroke in China: results from a nationwide population-based survey of 480 687 adults

Clopidogrel with aspirin in acute minor stroke or transient ischemic attack

Stroke in China: advances and challenges in epidemiology, prevention, and management

Near-real-time monitoring of global CO2Β emissions reveals the effects of the COVID-19 pandemic

Rivaroxaban for stroke prevention after embolic stroke of undetermined source

Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study

Summer soil drying exacerbated by earlier spring greening of northern vegetation